Dual Effect of DLBCL-derived EXOs in Lymphoma to Improve DC Vaccine Efficacy in Vitro While Favor Tumorgenesis in Vivo

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2018 Aug 15

PMID 30103789

Citations 44

Authors

Zhenzhen Chen

Liangshun You

Lei Wang

Xianbo Huang

Hui Liu

Ju Ying Wei

Li Zhu

Wenbin Qian

Affiliations

Soon will be listed here.

Abstract

Background: Exosomes derived from tumor cells (TEXs) are involved in both immune suppression, angiogenesis, metastasis and anticancer stimulatory, but the biological characteristics and role of diffuse large B cell lymphoma (DLBCL)-derived exosomes have been less investigated.

Methods: Exosomes (EXOs) were isolated from OCI-LY3, SU-DHL-16, and Raji cells and biological characteristics of EXOs were investigated using electron microscopy, flow cytometry analysis, and Western blot analysis. The protein expression of EXOs was determined by an antibody array. Next, the communication between EXOs and lymphoma cell, stromal cell, dendritic cells (DCs), and T cells was evaluated. Finally, effect of DLBCL TEXs on tumor growth in vivo was investigated.

Results: We demonstrated that EXOs derived from DLBCL cell lines displayed malignancy molecules such as c-Myc, Bcl-2, Mcl-1, CD19, and CD20. There was a different protein expression pattern between DLBCL TEXs and Burkitt lymphoma TEXs. DLBCL TEXs were easily captured by DCs and lymphoma cells, and mainly acted as an immunosuppressive mediator, evidenced by induction of apoptosis and upregulation of PD-1 in T cells. Furthermore, the TEXs stimulated not only cell proliferation, migration of stromal cells but also angiogenesis. As a result, the TEXs promoted tumor growth in vivo. On other hand, DLBCL TEXs did not induce apoptosis of DCs. After pulsed with the TEXs, DCs could stimulate clonal expansion of T cells, increase the secretion of IL-6 and TNFα, and decrease the production of immunosuppressive cytokine IL-4 and IL-10. The T cells from tumor bearing mice immunized by TEX were shown to possess superior antilymphoma potency relative to immunization of tumor lysates.

Conclusions: This study provides the framework for novel immunotherapies targeting TEXs in DLBCL.

Citing Articles

Therapeutic Vaccines for Hematological Cancers: A Scoping Review of This Immunotherapeutic Approach as Alternative to the Treatment of These Malignancies.

Mathias F, Carvalho M, Ruiz J Vaccines (Basel). 2025; 13(2).

PMID: 40006660 PMC: 11860334. DOI: 10.3390/vaccines13020114.

Extracellular vesicles in tumor immunity: mechanisms and novel insights.

Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.

PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.

Potential Effect of Extracellular Vesicles in Clinical Settings of Lymphoma.

Mamgain G, Yadav S Indian J Clin Biochem. 2025; 40(1):12-24.

PMID: 39835236 PMC: 11741971. DOI: 10.1007/s12291-023-01156-x.

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

Critical Role of Extracellular Vesicles in Diffuse Large B-Cell Lymphoma; Pathogenesis, Potential Biomarkers, and Targeted Therapy-A Narrative Review.

Punnachet T, Chattipakorn S, Chattipakorn N, Kumfu S Biomedicines. 2025; 12(12.

PMID: 39767730 PMC: 11673791. DOI: 10.3390/biomedicines12122822.

References

Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W . Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015; 8:83. PMC: 4496882. DOI: 10.1186/s13045-015-0181-x. View

Malaponte G, Hafsi S, Polesel J, Castellano G, Spessotto P, Guarneri C . Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. Biochim Biophys Acta. 2015; 1863(3):483-489. DOI: 10.1016/j.bbamcr.2015.09.018. View

Al-Hamadani M, Habermann T, Cerhan J, Macon W, Maurer M, Go R . Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015; 90(9):790-5. DOI: 10.1002/ajh.24086. View

Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S . High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumour Biol. 2015; 36(12):9739-52. DOI: 10.1007/s13277-015-3741-3. View

Ghayad S, Rammal G, Ghamloush F, Basma H, Nasr R, Diab-Assaf M . Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts. Sci Rep. 2016; 6:37088. PMC: 5112573. DOI: 10.1038/srep37088. View

Gu X, Erb U, Buchler M, Zoller M . Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int J Cancer. 2014; 136(4):E74-84. DOI: 10.1002/ijc.29100. View

You L, Mao L, Wei J, Jin S, Yang C, Liu H . The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses. J Hematol Oncol. 2017; 10(1):165. PMC: 5651564. DOI: 10.1186/s13045-017-0534-8. View

Oksvold M, Kullmann A, Forfang L, Kierulf B, Li M, Brech A . Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther. 2014; 36(6):847-862.e1. DOI: 10.1016/j.clinthera.2014.05.010. View

Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C . Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3):297-303. DOI: 10.1038/85438. View

10.

Chen J, Zurawski G, Zurawski S, Wang Z, Akagawa K, Oh S . A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40. J Hematol Oncol. 2015; 8:35. PMC: 4424584. DOI: 10.1186/s13045-015-0131-7. View

11.

Hao S, Bai O, Yuan J, Qureshi M, Xiang J . Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol. 2006; 3(3):205-11. View

12.

Filipazzi P, Burdek M, Villa A, Rivoltini L, Huber V . Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. 2012; 22(4):342-9. DOI: 10.1016/j.semcancer.2012.02.005. View

13.

Meng H, Jin Y, Liu H, You L, Yang C, Yang X . SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol. 2013; 6:18. PMC: 3599109. DOI: 10.1186/1756-8722-6-18. View

14.

Cho J, Lee Y, Kim S, Ko J, Kim C . MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2008; 275(2):256-65. DOI: 10.1016/j.canlet.2008.10.021. View

15.

Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J . Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2015; 22(5):1138-49. DOI: 10.1158/1078-0432.CCR-15-1191. View

16.

Nicholas N, Apollonio B, Ramsay A . Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochim Biophys Acta. 2015; 1863(3):471-482. DOI: 10.1016/j.bbamcr.2015.11.003. View

17.

Szczepanski M, Szajnik M, Welsh A, Whiteside T, Boyiadzis M . Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011; 96(9):1302-9. PMC: 3166100. DOI: 10.3324/haematol.2010.039743. View

18.

Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B . Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood. 2014; 123(14):2189-98. DOI: 10.1182/blood-2013-08-523886. View

19.

Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q . Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol. 2006; 36(6):1598-607. DOI: 10.1002/eji.200535501. View

20.

Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa S, Magni M . Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2008; 113(1):18-27. DOI: 10.1182/blood-2008-06-165654. View